Journal
STEROIDS IN NEUROENDOCRINE IMMUNOLOGY AND THERAPY OF RHEUMATIC DISEASES II
Volume 1318, Issue -, Pages 1-6Publisher
BLACKWELL SCIENCE PUBL
DOI: 10.1111/nyas.12364
Keywords
membrane-bound glucocorticoid receptor; nongenomic effects; estrogen receptor; progesterone receptor
Categories
Ask authors/readers for more resources
Glucocorticoids (GCs) are routinely used to treat a wide range of rheumatic and other inflammatory diseases. GCs are steroidal drugs that exert their strong anti-inflammatory and immunosuppressive effects via genomic mechanisms, primarily by signaling through the cytosolic glucocorticoid receptor. In addition, rapid, nongenomic responses following GC treatment have been reported to involve signaling via the membrane-bound glucocorticoid receptor (mGR). Since an important clinical role of this receptor has been proposed, investigations regarding the origin and function of the mGR are currently performed in order to understand rapid GC signaling and to optimize treatment strategies with GCs. Here, we summarize the current knowledge on the mGR and compare these findings to results obtained for other membrane-bound receptors, such as membrane forms of the estrogen and progesterone receptors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available